DIAXONHIT announces the CE marking of the BJI InoPlex(r)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DIAXONHIT announces the CE marking of the BJI InoPlex(r) test and its commercial launch

DIAXONHIT - Prosthetic joint infections test

DIAXONHIT announces the CE marking of the BJI InoPlex ® test

and its commercial launch

  • The first and only non-invasive serological test with a simple blood sample
  • Launched in France through InGen, DIAXONHIT Group's commercial affiliate
  • Upcoming European launch through already selected distributors

PARIS, Jan. 13, 2015 (GLOBE NEWSWIRE) -- DIAXONHIT (Alternext : ALEHT, FR0004054427), a French leader in specialty in-vitro diagnostics for transplantation, infectious diseases and cancer, announces today that the CE marking of its BJI InoPlex® diagnostic test, the first blood test to aid in the diagnosis of prosthetic bone and joint infections, was completed late 2014 as scheduled. This regulatory step concludes the test development cycle, and opens the way to commercialization by DIAXONHIT. The launch of BJI InoPlex® is planned for the first quarter 2015, directly through InGen in France and through distributors in Europe.

BJI Inoplex® : a unique and innovative test

BJI InoPlex® is the first diagnostic test that can detect in patients' blood antibodies against several bacteria types frequently responsible for prosthetic infections, in particular staphylococcus, the most often encountered type in such infections.

BJI InoPlex® performance was confirmed in a clinical validation study conducted in two French reference centers for prosthetic joint infections, and were presented at the 34 th RICAI meeting last November in Paris. During a symposium that gathered more than 200 participants, three specialists involved at different stages of prosthetic infections care presented the test and its use: Professor Eric Senneville, head of infectious and tropical diseases and infectiologist at the Tourcoing Hospital, Dr. Martin Rottman, microbiologist at the Raymond Poincaré Hospital (Paris Hospitals, AP-HP) and Dr. Thomas Bauer, orthopaedic surgeon at the Ambroise Paré Hospital (AP-HP) and study investigator. The speakers stressed the importance of improving current care of patients who developed prosthetic complications, whether mechanical or infectious. The speakers also stressed the importance of BJI InoPlex® in the diagnostic process in order to provide quick results and to propose a more appropriate therapy, treatments for mechanical complications being very different from those needed to treat infections.

BJI InoPlex®: in-house manufacturing

DIAXONHIT will manufacture in-house the BJI InoPlex® kit that includes all parts needed to perform the test on Luminex equipment. Kit manufacturing will be performed under quality assurance, based on compliance with ISO 13485 for which the DIAXONHIT Group is certified.

BJI InoPlex®: launch and initial commercialization in Q1 2015

DIAXONHIT is launching BJI InoPlex®. Commercialization in France is undertaken by its subsidiary InGen, leader in France for diagnostic tests related to transplantation and histocompatibility which, for the most part, are also performed on Luminex instruments. Beyond marketing the test, for which a medical expert was recruited, InGen will be in charge of sales administration, logistics for suppling kits to laboratories, reagent rental of Luminex instruments when necessary, and servicing.

For Europe, commercialization of the test will be undertaken through exclusive distribution agreements with distributors which DIAXONHIT already met and selected in November 2014 at the MEDICA convention in Düsseldorf, Germany, where the company had a booth.

BJI InoPlex®: an important step to accelerate DIAXONHIT's European Development
 
With the launch of this new proprietary test that strengthens its existing range of specialty diagnostic tests, DIAXONHIT further implements its development strategy.

In the coming years, the Group's objective is to become a European leader in specialty diagnostics and to achieve financial break-even by gradually increasing the share of proprietary products sales. This increase is directly linked to the innovation strategy and to R&D investments undertaken by DIAXONHIT in recent years.

After BJI InoPlex® should thus follow the DX15 test in thyroid cancer, but also the extension of the "InoPlex" range to other infectious indications.


" CE Marking BJI InoPlex® is a key step in the life of our group and a perfect illustration of our positioning in specialty in-vitro diagnostics. I would like to thank all our employees who participated in the development of this test, and took him to the gates of commercialization within the announced deadline. They demonstrate our ability to develop innovative high-value in-vitro diagnostic products and to strengthen our portfolio of marketed products. In early 2015, we will continue our innovation and business development by building on the strengths of our group, especially those that allow us to successfully implement our strategy. " concludes Dr. Loïc Maurel, President of the Management Board of Diaxonhit.

-------------------

About BJI InoPlex ® performance and clinical utility

Each year, nearly 3 million implants are placed in Europe and the United States, including more than 220,000 hip and knee replacements in France. About 10 to 20% of all patients undergoing replacements may experience pain or functional impairment, even long after implant surgery. Identifying whether the cause of such dysfunction is infectious or mechanical is key to prescribe the relevant treatment. Currently, diagnostic tools available to diagnose prosthetic infections have limited performances, resulting sometimes in unsuitable patient care and late diagnosis. Given that therapeutic strategies are quite different if the dysfunction is infectious or mechanical, it is critical for the surgeon, the infectiologist and the microbiologist to identify an infection prior to surgery.

BJI InoPlex® is a new test that provides qualitative information in a couple of hours for each targeted bacteria types, which enables caregivers, in association with the usual assessments, to accelerate and improve the care of patients. The performance of BJI InoPlex® compared with microbiological results on intraoperative samples are respectively 82.2% for specificity and 75.9% for sensitivity, all types of targeted staphylococci included. Other bacteria targeted by BJI InoPlex® are less frequent in the prevalence of prosthetic infections, and the incidence of proven intraoperative infections with these bacteria also ended up being limited in the study cohort. The high specificity of the test for these two families of bacteria (B-Streptococcus and Propionibacterium acnes) preferentially orients towards the absence of an immune response against these types of bacteria, BJI InoPlex® being used in addition to other tests performed.

This test requires a very small amount of serum (10 µl) taken by a simple blood draw and can be easily repeated. After adequate preparation, the test is carried out directly in the biology laboratory of the hospital with a standard Luminex instrument. The BJI InoPlex® kit contains various reagents necessary to perform the test, a 96-well filter plate, a calibration CD-ROM containing specific calibration information for each batch and a user manual. The BJI InoPlex® Software is used to interpret the data and report a result per family of bacteria.

BJI InoPlex® is protected by several patents covering the selected antigens.

About the CE mark and ISO 13485

The CE mark was created as part of European legislation. It materializes conformity of a product with EU requirements for the product manufacturer. Once CE marked, such a product can circulate freely in the European market, without any further requirement in terms of formalities, national safety standard or new testing. For Diaxonhit, BJI InoPlex® meets the requirements of Directive 98/79/CE of the European Parliament and the European Council with respect to medical devices for in-vitro diagnosis. Diaxonhit conducted the controls and tests that ensure compliance of BJI InoPlex® with the requirements set out in this Directive.

Diaxonhit drafted an EC declaration of conformity document in which Diaxonhit ensures that the product meets the "essential health and safety requirements" of relevant regulations, and by which it becomes liable.

The Diaxonhit Group is ISO 13485 : 2012 and ISO 9001 : 2008 since February 2014 (certification audit performed by the LNE, National Laboratory for Metrology and Testing, a french notified body). The Group meets the requirements of quality management systems (QMS) for the medical device industry, in its two areas of activity, Design of Medical Devices for In-vitro Diagnostics (reagent kit and associated software) in the area of infectious diseases, oncology and transplantation, and Distribution of Medical Devices for In-vitro Diagnostics (reagents and instruments) and associated services (training and maintenance).

About DIAXONHIT

Diaxonhit (Alternext, FR0004054427, ALEHT) is a French fully integrated leader in in vitro diagnostics, involved from research to commercialization of specialty diagnostic products in the fields of transplantation, infectious diseases and cancer. With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, in-vitro diagnostic kits and advanced equipment, quality control products and rapid tests, including Tetanus Quick Stick ®, a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest commercial partner worldwide. The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering its three main specialty areas: transplantation, immuno-infection and cancer. Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of both the Alternext OSEO Innovation and the Next Biotech indices. For more information, please visit: http://www.diaxonhit.com

Symbol : ALEHT - ISIN Code: FR0004054427  -  Reuters : ALEHT.PA  - Bloomberg : ALEHT:FP

Contacts

DIAXONHIT
Hervé Duchesne de Lamotte, CFO, +33 (0)1 53 94 52 49, herve.delamotte@diaxonhit.com

NewCap
Julien Perez, Investors Relations & Financial Communication, +33 (0)1 44 71 98 52, jperez@newcap.fr
Annie-Florence Loyer, Media Relations, +33 (0)1 44 71 98 50, afloyer@newcap.fr

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Press release (PDF) http://hugin.info/159969/R/1886714/667216.pdf

HUG#1886714

Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading